Fennec Pharmaceuticals Inc SEC Filings

Fennec Pharmaceuticals Inc. (FENC) has filed a Form S-8 to register securities for issuance under its Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan. This filing allows the company to issue equity-based awards such as stock options or other equity incentives to employees, directors and other eligible participants under that plan. The registration statement incorporates by reference Fennec’s latest Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, specified Current Reports on Form 8-K and its Form 8-A description of capital stock. The company also outlines how directors and officers may be indemnified under British Columbia corporate law and its Articles, and confirms it maintains liability insurance for directors and officers. Standard undertakings are included for future amendments and for how later Exchange Act reports will be treated as part of this registration.

Fennec Pharmaceuticals Inc. (FENC) entered into subscription agreements with certain existing institutional shareholders to sell an aggregate of 670,000 common shares at US$7.50 per share. This equity offering, made under a listed issuer financing exemption in Canada and registered on the company’s Form S-3 shelf, closed on November 18, 2025 and generated aggregate gross proceeds of US$5,025,000 before expenses.

Fennec plans to use the first portion of these proceeds to help repurchase and redeem its outstanding Petrichor convertible notes for an aggregate price of approximately US$21,729,455 on or before November 19, 2025, with any remaining net proceeds allocated to working capital and general corporate purposes.

Fennec Pharmaceuticals Inc. is registering and issuing 670,000 common shares at $7.50 per share, for aggregate gross proceeds of $5,025,000. These shares are being sold directly to certain existing institutional shareholders in Canada (excluding Quebec) under a listed issuer financing exemption, without using a broker or placement agent. The company recently completed a separate underwritten public offering of 5,366,667 common shares at $7.50 per share, raising approximately $40,250,000 in gross proceeds.

Combined net proceeds of approximately $42,014,502 are intended first to repurchase and redeem the Petrichor convertible notes for about $21,729,455, including outstanding principal, accrued interest and a redemption fee, with the balance earmarked for working capital and general corporate purposes. After giving effect to both offerings, Fennec’s as adjusted net tangible book value as of September 30, 2025 would rise from approximately $(0.16) to $1.10 per share, resulting in immediate dilution of about $6.40 per share to new investors.

Fennec Pharmaceuticals Inc. (FENC) received a Form 4 reporting sales of its common stock by a director and more than 10% owner group affiliated with Southpoint. On 11/14/2025, the reporting persons sold 160,100 shares of common stock at a weighted average price of $7.9977 per share. On 11/17/2025, they sold an additional 85,918 shares at a weighted average price of $8.7897 per share. Following these transactions, the group reports indirect beneficial ownership of 3,764,082 Fennec common shares through Southpoint Master Fund, LP and its related investment entities. The filing notes that each reporting person disclaims beneficial ownership beyond its or his pecuniary interest.

Fennec Pharmaceuticals Inc. is offering 4,666,667 common shares at $7.50 per share in an underwritten public offering, for gross proceeds of $35,000,003 and estimated net proceeds of $32,400,002 before the underwriters’ option. The company has granted underwriters a 30‑day option to buy up to 700,000 additional shares. A concurrent non‑brokered LIFE offering in Canada may raise up to an additional $5,025,000 but is not registered under this prospectus. Fennec plans to use the combined proceeds primarily to repurchase and redeem its Petrichor convertible notes for about $21,729,455 and apply any remaining funds to working capital and general corporate purposes. Following this offering and the Concurrent LIFE Offering, 33,453,496 common shares will be outstanding, or 34,153,496 if the option is fully exercised, compared with 28,116,829 shares outstanding as of November 12, 2025.

Fennec Pharmaceuticals Inc. entered into an underwriting agreement to conduct an underwritten public offering of 4,666,667 common shares. The shares will be sold to the public at $7.50 per share and purchased by the underwriters from the company at $6.975 per share, with Fennec receiving the net proceeds. The company also granted the underwriters a 30-day option to buy up to an additional 700,000 shares at the public offering price, less underwriting discounts and commissions.

The transaction is being carried out under an effective shelf registration statement on Form S-3, using a prospectus supplement and related prospectus. Piper Sandler & Co. and Craig-Hallum Capital Group LLC are acting as representatives of the underwriters, and the closing of the offering is expected on November 17, 2025, subject to customary conditions.

Fennec Pharmaceuticals filed a preliminary prospectus supplement for a primary offering of common shares. The company expects to use initial net proceeds to repurchase and redeem its outstanding Petrichor convertible notes, with an aggregate principal amount (inclusive of PIK interest) of approximately $19,769,076, which bear interest at prime (floor 3.5%) plus 4.5% and mature on August 19, 2027.

The offering includes a 30‑day option for underwriters to purchase additional shares. Fennec also plans a concurrent, non‑brokered Canadian LIFE offering on the same terms with certain existing institutional shareholders, which may close at the same time or shortly after and would dilute participants in this offering if completed. The common shares trade on Nasdaq as “FENC” and TSX as “FRX”; the last reported Nasdaq sale price was $7.78 on November 12, 2025. Shares outstanding were 28,116,829 as of November 12, 2025.

Fennec Pharmaceuticals (FENC) reported Q3 2025 results with PEDMARK net product sales of $12,462 (up from $6,974 a year ago). For the nine months, net product sales were $30,865 versus $21,655 in 2024. Q3 operating loss was $(189) and net loss was $(638), or $(0.02) per share.

Cash and cash equivalents were $21,947, total assets $49,261, and total liabilities $53,753, resulting in a stockholders’ deficit of $(4,492). The balance sheet reflects a term loan of $18,206 and accrued PIK interest of $1,271 under the Petrichor notes; following December 2024 redemptions, $19,477 remained outstanding as of September 30, 2025. Operating cash flow for the nine months was $(6,511); financing cash flow was $1,824.

The company continues to account for its 2024 Norgine license—approximately $43,000 was received upfront, with $24,561 recorded as long‑term contract liability. As of November 10, 2025, common shares outstanding were 28,116,829.

Fennec Pharmaceuticals (FENC) reported an insider transaction on a Form 4. Director Rosty Raykov sold 10,000 common shares on 11/05/2025 at $8.10 per share in an open-market sale. Following the transaction, he beneficially owns 82,318 shares, held directly.

The sale was made pursuant to a Rule 10b5-1 trading plan dated August 23, 2024, indicating pre‑arranged trading parameters.